^
Association details:
Evidence:
Evidence Level:
Sensitive: D – Preclinical
Source:
Title:

Sensitivity of colorectal or pancreatic cancers with high DDX5 and mutations in Kras and p53 genes to FL118 treatment.

Published date:
05/28/2020
Excerpt:
High expression of DDX5 (also called p68), a multifunctional oncogenic transcriptional co-activator and a DEAD-box RNA helicase, is associated with high FL118 efficacy in both CRC and PDAC PDX tumors….DDX5, mKras and mp53 appears to be favorable biomarkers for predicting FL118 high efficacy.
DOI:
10.1200/JCO.2020.38.15_suppl.e16102
Evidence Level:
Sensitive: D – Preclinical
New
Title:

FL118, acting as a 'molecular glue degrader', binds to dephosphorylates and degrades the oncoprotein DDX5 (p68) to control c-Myc, survivin and mutant Kras against colorectal and pancreatic cancer with high efficacy

Excerpt:
Our human tumour animal model studies further indicated that FL118 exhibits high efficacy to eliminate human PDAC and CRC tumours that have a high expression of DDX5...
DOI:
10.1002/ctm2.881